New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
09:45 EDTISIS, ISIS, BIIB, BIIBPiper Jaffray's biotech analyst holds an analyst/industry conference call
Analyst Schimmer discusses Isis Pharmaceuticals/Biogen's (ISIS/BIIB) SMNrx for Spinal Muscular Atrophy (SMA) on an Analyst/Industry conference call to be held on March 12 at 10 am.
News For ISIS;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 16, 2014
07:06 EDTISISIsis Pharmaceuticals initiates phase 1/2 study of ISIS-DMPK Rx
Subscribe for More Information
December 12, 2014
08:01 EDTBIIBPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
December 11, 2014
09:28 EDTISISIsis Pharmaceuticals up 3% after CEO appears on Mad Money
Subscribe for More Information
December 9, 2014
12:22 EDTBIIBPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
December 8, 2014
10:41 EDTISISIsis Pharmaceuticals price target raised to $81 from $62 at Piper Jaffray
Subscribe for More Information
08:00 EDTISISIsis Pharmaceuticals price target raised to $66 from $55 at Stifel
Subscribe for More Information
05:30 EDTISISIsis Pharmaceuticals to host conference call
Subscribe for More Information
December 3, 2014
18:29 EDTISISOn The Fly: After Hours Movers
Subscribe for More Information
17:09 EDTISISIsis Pharmaceuticals reports results from Phase 2 study of ISIS-APOCIII
Isis Pharmaceuticals announced that data from a Phase 2 study of ISIS-APOCIII in patients with familial chylomicronemia syndrome were published in The New England Journal of Medicine. The paper, titled "Targeting ApoC-III in the Familial Chylomicronemia Syndrome," show that patients with FCS treated with ISIS-APOCIII achieved substantial reductions in apoC-III, triglycerides, chylomicrons and apoC-III-associated very low density lipoprotein-cholesterol particles. The three FCS patients in this open-label study had baseline triglyceride levels ranging from 1,406 mg/dL to 2,083 mg/dL and all three patients achieved triglyceride levels below 500 mg/dL during the study. FCS is a rare genetic disorder characterized by severe elevated levels of triglycerides. Current treatment options do not adequately reduce triglycerides and, as a result, patients with FCS have increased risk of recurrent and potentially fatal pancreatitis and other complications.
07:05 EDTBIIBBiogen to present data from hematology programs at ASH meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use